Cover Image
Market Research Report

Global Actinic Keratosis Drugs Market 2020-2024

Published by TechNavio (Infiniti Research Ltd.) Product code 943515
Published Content info 120 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Actinic Keratosis Drugs Market 2020-2024
Published: June 11, 2020 Content info: 120 Pages
Description

Technavio has been monitoring the actinic keratosis drugs market and it is poised to grow by $ 520.14 mn during 2020-2024 progressing at a CAGR of 3% during the forecast period. Our reports on actinic keratosis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the high prevalence of actinic keratosis and availability of combination therapy. In addition, high prevalence of actinic keratosis is anticipated to boost the growth of the market as well.

The actinic keratosis drugs market analysis includes product segment and geographical landscapes

Technavio's ‘ actinic keratosis drugs market ’ is segmented as below:

By Product:

  • Nucleoside metabolic inhibitors
  • Immunomodulators
  • Photosensitizers
  • NSAIDs

By Geography: landscapes

  • North America
  • APAC
  • Europe
  • ROW

This study identifies the threat of conversion to fatal disease as one of the prime reasons driving the actinic keratosis drugs market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our actinic keratosis drugs market covers the following areas:

  • Actinic keratosis drugs market sizing
  • Actinic keratosis drugs market forecast
  • Actinic keratosis drugs market industry analysis"

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading actinic keratosis drugs market vendors that include 3M Co., Almirall SA, Bausch Health Companies Inc., Biofrontera AG, Hill Dermaceuticals Inc., LEO Pharma AS, Mylan NV, Nestle SA, Novartis AG, and Sun Pharmaceutical Industries Ltd.. Also, the actinic keratosis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents
Product Code: IRTNTR44052

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Drug class

  • Market segments
  • Comparison by Drug class
  • Nucleoside metabolic inhibitors - Market size and forecast 2019-2024
  • Immunomodulators - Market size and forecast 2019-2024
  • Photosensitizers - Market size and forecast 2019-2024
  • NSAIDs - Market size and forecast 2019-2024
  • Market opportunity by Drug class

Customer Landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • APAC - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Volume drivers - demand led growth
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • 3M Co.
  • Almirall SA
  • Bausch Health Companies Inc.
  • Biofrontera AG
  • Hill Dermaceuticals Inc.
  • LEO Pharma AS
  • Mylan NV
  • Nestle SA
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ million)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Other1 - Market share 2019-2024 (%)
  • 22: Comparison by Other1
  • 23: Nucleoside metabolic inhibitors - Market size and forecast 2019-2024 ($ million)
  • 24: Nucleoside metabolic inhibitors - Year-over-year growth 2019-2024 (%)
  • 25: Immunomodulators - Market size and forecast 2019-2024 ($ million)
  • 26: Immunomodulators - Year-over-year growth 2019-2024 (%)
  • 27: Photosensitizers - Market size and forecast 2019-2024 ($ million)
  • 28: Photosensitizers - Year-over-year growth 2019-2024 (%)
  • 29: NSAIDs - Market size and forecast 2019-2024 ($ million)
  • 30: NSAIDs - Year-over-year growth 2019-2024 (%)
  • 31: Market opportunity by Other1
  • 32: Customer landscape
  • 33: Market share by geography 2019-2024 (%)
  • 34: Geographic comparison
  • 35: North America - Market size and forecast 2019-2024 ($ million)
  • 36: North America - Year-over-year growth 2019-2024 (%)
  • 37: APAC - Market size and forecast 2019-2024 ($ million)
  • 38: APAC - Year-over-year growth 2019-2024 (%)
  • 39: Europe - Market size and forecast 2019-2024 ($ million)
  • 40: Europe - Year-over-year growth 2019-2024 (%)
  • 41: ROW - Market size and forecast 2019-2024 ($ million)
  • 42: ROW - Year-over-year growth 2019-2024 (%)
  • 43: Key leading countries
  • 44: Market opportunity by geography ($ million)
  • 45: Impact of drivers and challenges
  • 46: Vendor landscape
  • 47: Landscape disruption
  • 48: Industry risks
  • 49: Vendors covered
  • 50: Market positioning of vendors
  • 51: 3M Co. - Overview
  • 52: 3M Co. - Business segments
  • 53: 3M Co. - Key offerings
  • 54: 3M Co. - Key customers
  • 55: 3M Co. - Segment focus
  • 56: Almirall SA - Overview
  • 57: Almirall SA - Product and service
  • 58: Almirall SA - Key offerings
  • 59: Almirall SA - Key customers
  • 60: Almirall SA - Segment focus
  • 61: Bausch Health Companies Inc. - Overview
  • 62: Bausch Health Companies Inc. - Business segments
  • 63: Bausch Health Companies Inc. - Key offerings
  • 64: Bausch Health Companies Inc. - Key customers
  • 65: Bausch Health Companies Inc. - Segment focus
  • 66: Biofrontera AG - Overview
  • 67: Biofrontera AG - Product and service
  • 68: Biofrontera AG - Key offerings
  • 69: Biofrontera AG - Key customers
  • 70: Biofrontera AG - Segment focus
  • 71: Hill Dermaceuticals Inc. - Overview
  • 72: Hill Dermaceuticals Inc. - Product and service
  • 73: Hill Dermaceuticals Inc. - Key offerings
  • 74: Hill Dermaceuticals Inc. - Key customers
  • 75: Hill Dermaceuticals Inc. - Segment focus
  • 76: LEO Pharma AS - Overview
  • 77: LEO Pharma AS - Business segments
  • 78: LEO Pharma AS - Key offerings
  • 79: LEO Pharma AS - Key customers
  • 80: LEO Pharma AS - Segment focus
  • 81: Mylan NV - Overview
  • 82: Mylan NV - Business segments
  • 83: Mylan NV - Key offerings
  • 84: Mylan NV - Key customers
  • 85: Mylan NV - Segment focus
  • 86: Nestle SA - Overview
  • 87: Nestle SA - Business segments
  • 88: Nestle SA - Key offerings
  • 89: Nestle SA - Key customers
  • 90: Nestle SA - Segment focus
  • 91: Novartis AG - Overview
  • 92: Novartis AG - Business segments
  • 93: Novartis AG - Key offerings
  • 94: Novartis AG - Key customers
  • 95: Novartis AG - Segment focus
  • 96: Sun Pharmaceutical Industries Ltd. - Overview
  • 97: Sun Pharmaceutical Industries Ltd. - Business segments
  • 98: Sun Pharmaceutical Industries Ltd. - Key offerings
  • 99: Sun Pharmaceutical Industries Ltd. - Key customers
  • 100: Sun Pharmaceutical Industries Ltd. - Segment focus
  • 101: Currency conversion rates for US$
  • 102: Research Methodology
  • 103: Validation techniques employed for market sizing
  • 104: Information sources
  • 105: List of abbreviations
Back to Top